- Archives
-
-
-
-
-
-
-
-
-
-
How will Contract Service Providers help?
Gil Y. Roth
Contract research firms respond to client needs
Steven Heffner
Have Wyeth & Pfizer changed the market?
Scott Lundstrom
Advice for CEOs & senior management
Paul Woitach
Know what you're asking for from your CMO
Linda D. Bentley
Not a market for the faint-hearted
Dr. Faiz Kermani
New coding and marking technologies can help combat counterfeiting, comply with FDA regs and increase profits
Richard Jushchyshyn, Rich Holzchuh and Xavier Chaveton
CDISC and the Study Data Tabulation Model
Tom Guinter
Our editorial staff has gathered information from annual reports, interviews, and analyst coverage to compile a list of the previous year's Top 20 players in the Pharma arena.
The Top 10 Biopharma rankings saw two more companies reach the billion-dollar mark in revenues in 2004, as Gilead and MedImmune crossed that threshold. Unfortunately, a bad case of the flu sent Chiron back under the billion-dollar mark, as its fluvirin vaccine revenues dropped from $219 million in 2003 to a mere $2 million last year, after its well-documented manufacturing problems.
Gil Y. Roth
The impact of disposable bioreactors on the CMO industry
Sandra Fox
How client and vendor can reach accord
Marc Wolfgang
Promises and reality, measured out against the past
Jack Gardner
Global read, alliances and EDC continue to grow
Kristin Brooks
Connected by process, concerned with progress
Tom Spurgeon
How to implement a new model
Kim Oliver
Regulatory pressures fuel method development
Gil Y. Roth
With great power comes great responsibilities
Faiz Kermani and Camille Lovell-Hoare
A one-stop reference of the terminology of the Pharma and Biopharma Industry
Gil Y. Roth
Identifying the markets for injectable outsourcing
Gil Y. Roth
Can we sidestep the 'buy vs. make' decision?
Geoffrey Hodge
The risk-based revolution in IT
Kristin Brooks
Labels grow more sophisticated to match counterfeiting concerns and regulatory pressures
Leah Genuario
Our year-end review of merger & acquisition activity
Michael A. Martorelli
The FDA's manufacturing initiative picks up steam
Tom Spurgeon
|
